Rockefeller Capital Management
INBX icon

Rockefeller Capital Management’s Inhibrx INBX Stock Holding History

Rockefeller Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13
Closed -$1.03K – 4792
2025
Q4 		$1.03K Hold
13
– – ﹤0.01% 4447
2025
Q3 		$438 Buy
+13
New +$320 ﹤0.01% 4284

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Rockefeller Capital Management's INBX Position: Q1 2026 in Review

Rockefeller Capital Management sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 13 shares — an estimated $1.03K sold.

Rockefeller Capital Management first reported a position in INBX in Q3 2025 and held it in 2 quarters. The position peaked at $1.03K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Rockefeller Capital Management reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 13 Inhibrx shares in Q1 2026, an estimated $1.03K.
  • Rockefeller Capital Management first reported a position in Inhibrx in Q3 2025 and held it in 2 quarters.
  • Rockefeller Capital Management's Inhibrx position peaked at $1.03K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.